Compare

Brainstorm Cell Therapeutics Inc. vs Abpro Holdings, Inc. vs Adaptin Bio, Inc. vs Estrella Immunopharma, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Brainstorm Cell Therapeutics Inc. BCLI	Abpro Holdings, Inc. ABPO	Adaptin Bio, Inc. APTN	Estrella Immunopharma, Inc. ESLA
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$10.31M	-$2.89M	-$5.17M	-$13.06M
EPS (Diluted)	-$1.11	-$1.30	-$0.66	-$0.35
Operating cash flow	-$6.97M	-$6.01M	-$4.78M	-$1.79M
Free cash flow	n/a	n/a	n/a	n/a
Cash & equivalents	$29.0K	n/a	$459.2K	$1.38M
Total assets	$1.02M	$1.06M	$619.2K	$3.18M
Total liabilities	$11.01M	n/a	$2.11M	$13.54M
Shareholders' equity	-$9.98M	-$8.83M	-$1.49M	-$10.37M
Return on year-end equity	n/a	n/a	n/a	n/a
Shares outstanding	11.03M	2.73M	8.66M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Brainstorm Cell Therapeutics Inc.	Abpro Holdings, Inc.	Adaptin Bio, Inc.	Estrella Immunopharma, Inc.
Latest	n/a	$183.0K Ended 2024-12-31	n/a	n/a
1 year earlier	n/a	$122.0K Ended 2023-12-31	n/a	n/a
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a